Page last updated: 2024-10-28

fasudil and Osteosarcoma

fasudil has been researched along with Osteosarcoma in 1 studies

fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.

Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Xia, Y1
Cai, X1
Fan, J1
Zhang, L1
Li, Z1
Ren, J1
Wu, G1
Zhu, F1

Other Studies

1 other study available for fasudil and Osteosarcoma

ArticleYear
RhoA/ROCK pathway inhibition by fasudil suppresses the vasculogenic mimicry of U2OS osteosarcoma cells in vitro.
    Anti-cancer drugs, 2017, Volume: 28, Issue:5

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell

2017